ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 1506

Cognitive Impairment Prevalence and Most Affected Domains in Patients with SLE by the ACR Comprehensive Neuropsychological Battery

Chrisanna Dobrowolski1, Juan Pablo Diaz Martinez2, Kathleen Bingham2, Michelle Barraclough3, Roberta Kretzmann2, Maria Carmela Tartaglia4, Lesley Ruttan5, May Choi6, Simone Appenzeller7, Sherief Marzouk2, Dennisse Bonilla2, Patti Katz8, Dorcas Beaton9, Robin Green2, Joan Wither2, Laura Patricia Whittall Garcia2, Dafna Gladman10 and Zahi Touma11, 1Icahn School of Medicine at Mount Sinai, New York, NY, 2University Health Network, Toronto, ON, Canada, 3The University of Manchester, Manchester, United Kingdom, 4University Health Network, University of Toronto, Toronto, ON, Canada, 5Toronto Rehab/University Health Network - University Centre, Toronto, Canada, 6University of Calgary, Calgary, AB, Canada, 7Unicamp, Campinas, SP, Brazil, 8UCSF, San Rafael, CA, 9Institute for Work & Health, Toronto, ON, Canada, 10University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 11University of Toronto, Toronto, ON, Canada

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Cognitive dysfunction, Cohort Study, neuropsychiatric disorders, Neuropsychological Assessment, Systemic lupus erythematosus (SLE)

Session Information

Date: Sunday, November 17, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus (SLE) has a well-established association with cognitive impairment (CI) and confers worse quality of life. We previously presented descriptive data regarding the prevalence and characteristics of CI in an inception lupus cohort in 20191. Here, we present expanded, updated prevalence and domain involvement, along with variations in clinical characteristics in those with CI versus those without.

Methods: Patients with SLE between the ages of 18 and 65 years were recruited from a single center from July 2016 to May 2024. Each consenting patient completed the American College of Rheumatology (ACR) neuropsychological battery (NB), and clinical and demographic information was gathered. The NB measures six key domains of cognition. Both in-person and virtual NB were administered. Raw NB scores were compared to age- and sex-matched normative data. Participants were classified as having CI using two definitions: 1) z-score of ≤-1.5 in two or more cognitive domains, or 2) z-score of ≤-2 in two or more cognitive domains. Participants were classified as having ‘indeterminate cognition’ if they had z-scores in only one domain meeting the above cut offs and as having ‘normal cognition’ if no scores met these cutoffs.

Results: 362 participants were enrolled. Mean age was 40.6 years and 38 (10.8%) were male. White participants were more likely to be unimpaired (Table 1). Demographic profiles were otherwise similar between groups. Prevalence of CI was n=144/362 (44.3%) based on Definition 1, and n=96/362 (30.1%) based on Definition 2. Prior data showed similar results, n=118/279, (42.3%, Definition 1). Definition 2 has been updated and no direct comparison is feasible (previously defined CI as z-score of ≤-2 in one or more domain). We have now also excluded motor speed and dexterity as data was not missing at random (high prevalence of arthritis or joint damage in our cohort leading to missing data in these patients).

Prior data also revealed that the most commonly affected domains were learning and memory (n=147/279, 44.1%) and visual spatial construction (n=94/279, 33.3%) (Definition 1). Current data show that visual spatial construction is most frequently impaired at n=193/362, 51.7% (Definition 1); n=150/362, 39.4% (Definition 2). Learning and memory was also frequently impaired n=130/362 (34.1% (Definition 1); n=93/362, 23.6% (Definition 2). Verbal fluency and executive function were infrequently affected (Figure 1).

Conclusion: In this cohort of 362 patients, the prevalence of SLE-CI has remained stable over the past five years, reaching 44%. The most frequently affected cognitive domains remain visual spatial function, and learning and memory. Further studies are ongoing to determine underlying pathogenesis and treatment for this challenging and complex complication of SLE.

1Moghaddam B et al. Prevalence of Cognitive Impairment in an Inception Lupus Cohort as Assessed by a Comprehensive Neuropsychological Battery [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Supporting image 1

Figure 1: Baseline Prevalence of Cognitive Impairment and Affected Domains as Determined by the ACR Comprehensive Neuropsychological Battery

z-score ≤_1.5 (left); z-score ≤_2 (right).
Global: Impaired cognition = two or more domains impaired; Indeterminate = one domain impaired; Unimpaired = does not meet above criteria.
Domain 2, Simple attention and processing.
Domain 3, Visual spatial construction.
Domain 4, Verbal fluency.
Domain 5, Verbal and visuospatial learning and memory.
Domain 6, Executive function.

Supporting image 2

Table 1: Baseline Demographics Based on Prevalence of Cognitive Impairment

Impaired cognition, two or more domains with z-scores of ≤_1.5.
Indeterminate, one domain with z-score of ≤_1.5.
Unimpaired, does not meet prior criteria.
SLEDAI, Systemic lupus erythematosus disease activity index.
APLA, antiphospholipid antibodies present.


Disclosures: C. Dobrowolski: None; J. Diaz Martinez: None; K. Bingham: None; M. Barraclough: None; R. Kretzmann: None; M. Tartaglia: None; L. Ruttan: None; M. Choi: AbbVie/Abbott, 2, 6, Amgen, 2, 6, AstraZeneca, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Celgene, 2, 6, Celltrion, 2, Eli Lilly, 2, 6, GlaxoSmithKlein(GSK), 2, Janssen, 2, 6, Mallinckrodt Pharmaceuticals, 2, Merck/MSD, 2, MitogenDx, 8, Organon, 2, Pfizer, 2, 6, Roche, 2, Werfen, 2; S. Appenzeller: None; S. Marzouk: None; D. Bonilla: None; P. Katz: None; D. Beaton: None; R. Green: None; J. Wither: AstraZeneca, 1, 2, Pfizer, 5; L. Whittall Garcia: None; D. Gladman: AbbVie, 2, 5, Amgen, 2, 5, AstraZeneca, 2, BMS, 2, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5; Z. Touma: None.

To cite this abstract in AMA style:

Dobrowolski C, Diaz Martinez J, Bingham K, Barraclough M, Kretzmann R, Tartaglia M, Ruttan L, Choi M, Appenzeller S, Marzouk S, Bonilla D, Katz P, Beaton D, Green R, Wither J, Whittall Garcia L, Gladman D, Touma Z. Cognitive Impairment Prevalence and Most Affected Domains in Patients with SLE by the ACR Comprehensive Neuropsychological Battery [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cognitive-impairment-prevalence-and-most-affected-domains-in-patients-with-sle-by-the-acr-comprehensive-neuropsychological-battery/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cognitive-impairment-prevalence-and-most-affected-domains-in-patients-with-sle-by-the-acr-comprehensive-neuropsychological-battery/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology